Related Experiment Video
Updated: Mar 30, 2026
Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement
Published on: December 11, 2017
Design and rationale of the EMPagliflozin after Aortic Valve Replacement (EMPAVR) study: A randomized clinical trial
Louise Marqvard Sørensen1, Marie Sofie Reinert1, Anna Axelsson Raja1
1Department of Cardiology, The Heart Center, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
Insights
The EMPAVR study investigates if empagliflozin improves left ventricular remodeling after transcatheter aortic valve implantation for aortic stenosis. This trial may offer new insights into treating valvular heart disease.
Area of Science:
- Cardiology
- Pharmacology
- Medical Imaging
Background:
- Left ventricular (LV) hypertrophy and dysfunction are central to aortic stenosis (AS) pathophysiology.
- A significant portion of patients experience insufficient symptomatic benefit post-aortic valve replacement (AVR), potentially due to inadequate LV remodeling.
- Sodium-glucose cotransporter-2 (SGLT2) inhibitors show efficacy in heart failure (HF) and improve LV remodeling.
Purpose of the Study:
- To evaluate the effect of empagliflozin on left ventricular mass in patients with severe symptomatic AS undergoing transcatheter aortic valve implantation (TAVI).
- To assess the potential of SGLT2 inhibition to improve LV remodeling in the context of AS and TAVI.
Main Methods:
- The EMPAVR study is a randomized, double-blind, placebo-controlled trial.
- Patients with severe symptomatic AS undergoing TAVI are randomized 1:1 to receive empagliflozin or placebo for 180 days.
- The primary outcome is the change in LV mass indexed to body surface area, measured by cardiac CT from pre-AVR to 6 months post-AVR.
Main Results:
- This section is not available in the provided abstract.
Conclusions:
- The EMPAVR study is the first placebo-controlled trial examining SGLT2 inhibition post-TAVI for AS.
- Findings may guide LV treatment strategies in valvular heart disease and enhance understanding of aortic stenosis.
- The study has the potential to benefit patients globally with AS and related LV dysfunction.
Introduction:
Left ventricular (LV) hypertrophy and dysfunction secondary to aortic stenosis (AS) are key components of the disease's underlying pathophysiology. Previous trials suggest that up to 1/3 of patients do not benefit symptomatically after aortic valve replacement (AVR), which could be explained by insufficient LV remodeling. Sodium‒glucose cotransporter-2 (SGLT2) inhibitors are effective in heart failure (HF) and have been shown to improve LV remodeling (change in LV mass).
Methods:
The EMPAVR study is an investigator-initiated, randomized, placebo-controlled, and double-blinded trial comparing the effect of empagliflozin to placebo in patients with severe and symptomatic AS undergoing transcatheter aortic valve implantation (TAVI). The primary outcome for the EMPAVR trial is the difference in LV mass indexed to body surface area (measured by cardiac CT) from pre-AVR to 6 months post-AVR. Patients are randomized in a 1:1 ratio to 180 days of treatment.
Discussion:
To the best of our knowledge, the EMPAVR study is the first placebo-controlled trial investigating the effects of SGLT2 inhibition in patients following TAVI because of AS. The EMPAVR study has the potential to pave the way for treatment of the LV in valvular heart disease and may help patients worldwide and expand our understanding of aortic stenosis.
Trial Registration:
The EMPAVR study was registered in December 2024 (Clinical Trial Registration number: NCT06171802) before enrollment of the first patient. All patients will provide oral and written informed consent. The EMPAVR study is approved by the Regional Committee on Health Research Ethics and the Danish Medicines Agency.
Related Concept Videos
01:25Aortic Regurgitation III: Medical Management
01:15Aortic Regurgitation I: Introduction